stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

EL.En. S.p.A.

Italy · Milan: ELN.MI · Market cap: $1.51B · P/E: 26.4

EL.En. makes laser systems for doctors and manufacturers, selling them around the world.

EL.En. is an Italian company that builds lasers — not the kind you point at a cat, but the kind a surgeon uses to cut tissue or a factory uses to cut metal. It sells these systems to hospitals, clinics, and manufacturers around the world, and it makes money both from the machines themselves and from the parts and service they need over their long lives.

EL.En. S.p.A. (ELN.MI) Medical and aesthetic lasers: line art illustration of A medical laser console with a handheld treatment wand on an articulated arm
Medical lasers
El.En. makes lasers used in skin treatments and surgery.

The company runs two main businesses. The medical side makes laser and light-based machines for surgery, dermatology, aesthetics, and physical therapy, sold under brands like Deka and Cynosure, which EL.En. acquired in 2023 for roughly $290 million. The industrial side makes high-power lasers used for cutting, welding, and marking in factories, sold through its Cutlite and Lasit units. Medical is the bigger and faster-growing piece, and it's the one that gets the most attention from investors. The beauty and aesthetics market is the real engine here. Cynosure's machines handle hair removal, skin resurfacing, and body contouring, and clinics pay serious money for them because their customers keep coming back. That business is cyclical in a way medicine usually isn't — when consumers tighten their belts, they delay that laser treatment — and it faces plenty of competition from rivals like InMode and Lumenis (privately held). The industrial laser side is steadier but far more commoditized, competing against giants like IPG Photonics and Chinese manufacturers who compete hard on price.


EL.En. is headquartered near Florence, in Calenzano, and it's a genuine Italian success story — founded in 1981 by engineers who spun laser know-how out of university research. It pays a dividend and has generally kept its balance sheet tidy, funding the Cynosure deal without wrecking its finances. The thing to watch is whether the aesthetics boom holds up and whether Cynosure can justify that price tag; the industrial side is more of a steady background hum than a growth story.

Saved answer · last researched 12 Nov 2026